Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38599806)

  • 21. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
    Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
    Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].
    Zhou Q; Shi Y; Chen J; Liu B; Wang Y; Zhu D; Zhang HT; Xu P; Gong Y; Chen G; Wei S; Qiu X; Niu Z; Chen X; Lei Z; Duan L; Wu Z
    Zhongguo Fei Ai Za Zhi; 2011 Feb; 14(2):86-106. PubMed ID: 21342639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients.
    Maneenil K; Xue Z; Liu M; Boland J; Wu F; Stoddard SM; Molina J; Yang P
    Clin Lung Cancer; 2018 May; 19(3):e323-e333. PubMed ID: 29454534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinicopathological features and prognosis of SMARCA4-deficient non-small cell lung carcinoma: an analysis of 127 cases].
    Li SL; Wu CY; Zhang LP; Huang Y; Wu W; Zhang W; Hou LK
    Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):665-670. PubMed ID: 37408395
    [No Abstract]   [Full Text] [Related]  

  • 26. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
    Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
    J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results database.
    Rahouma M; Kamel M; Narula N; Nasar A; Harrison S; Lee B; Stiles B; Altorki NK; Port JL
    Eur J Cardiothorac Surg; 2018 Apr; 53(4):828-834. PubMed ID: 29240878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.
    Liang Z; Zhang E; Duan L; Weygant N; An G; Hu B; Yao J
    Technol Cancer Res Treat; 2022; 21():15330338211068960. PubMed ID: 35179409
    [No Abstract]   [Full Text] [Related]  

  • 30. Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma.
    Ağaçkıran Y; Aksu F; Akyürek N; Ercan C; Demiröz M; Aksu K
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):280-288. PubMed ID: 32929886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report.
    Xu L; Tao NN; Liang B; Li DW; Li HC; Su LL
    Thorac Cancer; 2022 Feb; 13(3):502-505. PubMed ID: 34953097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
    Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R;
    Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
    Zhou F; Huang Y; Cai W; Li J; Su C; Ren S; Wu C; Zhou C
    Lung Cancer; 2021 Mar; 153():66-72. PubMed ID: 33454519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
    Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
    Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological Features and Prognosis of Lung Adenocarcinoma Patients With K-RAS Gene Mutation.
    Sun D; Liu Y; Li P; Yang P; Yu G
    Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):406-413. PubMed ID: 37338109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic changes in PD-L1 expression and CD8
    Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
    Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.